FDA Approved: AUGTYRO — Original Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

FDA approves AUGTYRO (repotrectinib) from E.R. Squibb & Sons as the original approval. The indication covers NTRK gene fusion solid tumors, a tissue-agnostic ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion Solid Tumors

Drugs mentioned

• AUGTYRO (repotrectinib)

Snippet

ORIG AP for AUGTYRO (REPOTRECTINIB)